Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Combinations of AL-335, Odalasvir (ODV) and Simeprevir (SMV) in the Treatment of Chronic Hepatitis C Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Individuals with chronic hepatitis C virus (HCV) genotype 1, 2, 4, 5 or 6 infection~* Documented as treatment naive or experienced with a prior regimen consisting of Interferon (IFN) +/-Ribavirin (RBV) regimen without achieving sustained viral response~* Absence of cirrhosis~* Screening laboratory values within defined thresholds~* Must use specific contraceptive methods if female of childbearing potential or sexually active male~Exclusion Criteria:~* Co-infection with human immunodeficiency virus (HIV) or hepatitis B virus (HBV)~* Prior exposure to an HCV direct-acting antiviral agent (DAA), either in combination with pegylated interferon (PegIFN) or IFN-free~* Current or prior history of clinical hepatic decompensation~* History of clinically significant illness or any other medical disorder including cardiovascular conditions that may interfere with individual's treatment, assessment or compliance with the protocol~* Pregnant or a nursing female

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Group A (Type: EXPERIMENTAL): AL-335 (800 mg), odalasvir (25 mg) and simeprevir (75 mg) once daily during 6 weeks.
- Group B (Type: EXPERIMENTAL): AL-335 (800 mg), odalasvir (25 mg) and simeprevir (75 mg) once daily during 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).